- Cannabis-Induced Oceanic Boundlessness - I recently came across a study that phrased the subjective measure of their study in one of the most elegant ways I’ve read. The participants of the study found that high doses of THC created a state of “Cannabis-induced oceanic boundlessness”. The researchers found that the objectives of large doses of cannabis can help improve symptoms of treatment-resistant depression and other mental ailments, including distress related to cancer, and even dependence on cigarettes and alcohol. The study found that high doses of cannabis resulted in 17-19% of people with treatment-resistant depression and distress reporting experiencing “breakthroughs” for the better in their mental health. Interestingly, for those investigating psychedelics, Psilocybin was still reported as offering more positive mental “breakthroughs” for people with treatment-resistant depression, 59% of respondents. The study defines this breakthrough or feeling of “oceanic boundlessness” as mystical experiences, which often proceed a change in mental health. Study Reference - link - content reference - link
- A Cannabis Hangover - I find it very hard to comprehend how businesses setting up large cultivation operations around the world are not paying close to the following FACTS. Cannabis producers in Canada have sold less than 20% of their production since the country launched adult-use sales in October 2018, according to an MJBizDaily analysis. The newest data – which runs through 2020 – implies that most of the cannabis produced from 2018 through last year was either stored in inventory or destroyed, and less than one-fifth ended up in retail stores. That disconnect likely helps explain how the largest Canadian cannabis producers, which account for most of the industry’s production, together have lost more than 11 billion Canadian dollars ($8.8 billion) cumulatively. Content sourced from MMJBIZ
- U.K. Cannabis Care - It has been estimated that up to 1.4 million people in the UK are using cannabis for medical purposes, but while some of these individuals are being prescribed products by private GPs and pharmacies, others are buying CBD oils of different concentrations from health food shops or the whole plant extract from recreational dealers. According to Prohibition Partners, a marketing consultancy with a stated mission to open up the international cannabis industry, the entire UK cannabis market could be worth $1.7bn by 2024, if recreational use is also legalised in the next three years. Content reference - link
- Defining ‘What Is Cannabis' - a very important question - I came across the following thought-provoking quote - “The main issue we have is that medical cannabis use is still very poorly defined,” says Marta Di Forti, a psychiatrist at King’s College London. “When you look at the data out there, you don’t just have medicinal cannabis under one umbrella, you have different substances, taken at different doses, and sometimes combined with other medications and sometimes on their own. Because of this, when I have patients who want to buy CBD over the counter and try it, my recommendation is that they start with the lowest recommended dose and monitor if they experience any adverse side-effects because we still know so little.” “We’ve seen this in the past with tobacco, which was once advertised as a way to reduce anxiety. I don’t want to see history repeating itself.” This is a very important consideration as thoughts like this help define what is cannabis, and how to regulate it as a medicine.
Mater researchers aim to prove the benefits of cannabis for cancer patients
ECS Botanics jumps almost 5pc on $4.5 million Polish deal
Auscann commences Australian product registration with first regulatory filing for Dermacann®
Cann Group seeks to raise A$20 million
